Trial · NCT04126733
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator | Regorafenib Plus Nivolumab | 7.1 | 95% Confidence Interval 2.4 to 15.9 | percentage (%) of participants | |
| Duration of Response (DOR) | Regorafenib Plus Nivolumab | NA | 95% Confidence Interval 16.14 to NA | weeks | |
| Disease Control Rate (DCR) at 8 and 16 Weeks | Regorafenib Plus Nivolumab | Disease Control Rate at 8 weeks | 38.6 | 95% Confidence Interval 27.2 to 51.0 | percentage (%) of participants |
| Disease Control Rate (DCR) at 8 and 16 Weeks | Regorafenib Plus Nivolumab | Disease Control Rate at 16 weeks | 38.6 | 95% Confidence Interval 27.2 to 51.0 | percentage (%) of participants |
| Disease Control Rate (DCR) at 8 and 16 Weeks | Regorafenib Plus Nivolumab | Disease Control Rate at 24 weeks | 38.6 | 95% Confidence Interval 27.2 to 51.0 | percentage (%) of participants |
| Disease Control Rate (DCR) at 8 and 16 Weeks | Regorafenib Plus Nivolumab | Disease Control Rate at 32 weeks | 38.6 | 95% Confidence Interval 27.2 to 51.0 | percentage (%) of participants |
| Disease Control Rate (DCR) at 8 and 16 Weeks | Regorafenib Plus Nivolumab | Disease Control Rate at 40 weeks | 38.6 | 95% Confidence Interval 27.2 to 51.0 | percentage (%) of participants |
| Progression-free Survival (PFS) | Regorafenib Plus Nivolumab | 8.00 | 95% Confidence Interval 7.86 to 10.57 | weeks | |
| Overall Survival (OS) | Regorafenib Plus Nivolumab | 51.86 | 95% Confidence Interval 30.29 to 69.71 | weeks | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Any AEs | 69 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Serious AEs | 34 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Worst grade: Grade 1 | 3 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Worst grade: Grade 2 | 18 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Worst grade: Grade 3 | 38 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Worst grade: Grade 4 | 7 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Worst grade: Grade 5 (death) | 3 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Worst grade: Grade 1 or 2 | 21 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Worst grade: Grade 3 or 4 | 45 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Worst grade: Grade 3, 4, or 5 | 48 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5 | Regorafenib Plus Nivolumab | Grade 5 (death) between Day X+1 and Day 30 | 3 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04126733/results